Resuscitative Effect of Centhaquine (Lyfaquin®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial

WILLOWBROOK, Ill., May 10, 2021 /PRNewswire/ --  Pharmazz, Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care. The Company is marketing Centhaquine Citrate, with the brand name Lyfaquin® to health care professionals in India.

Pharmazz is pleased to announce the peer-reviewed publication of the manuscript titled "Resuscitative Effect of Centhaquine (Lyfaquin^®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial." The manuscript is published in Advances in Therapy and is available for download at https://link.springer.com/article/10.1007/s12325-021-01760-4.

Hypovolemic shock is a life-threatening condition due to intravascular volume depletion by extracellular fluid loss or blood loss. The current standard of care is inadequate and resuscitative agents are decades old. Attempts to develop an effective resuscitative agent have not been successful. 

In this phase II study, centhaquine (Lyfaquin^®) was safe and well-tolerated in hypovolemic shock patients. This study is the first to assess the effect of centhaquine on clinical outcomes in patients in hypovolemic shock due to blood loss. Centhaquine was highly efficacious, with statistically significant improvements in blood lactate levels, base deficit, and blood pressure. The percent time in the intensive care unit and ventilator support was less in the centhaquine group than in the control group. The total amount of vasopressors needed in the first 48 hours of resuscitation was lower in the centhaquine group than in the control group. An increase in systolic and diastolic blood pressure from baseline through 48 hours was more marked in the centhaquine group than in the control group. Improvements in base deficit, multiple organ dysfunction syndrome score, and adult respiratory distress syndrome were greater in the centhaquine group than in the control group.

An improvement in all the above clinical and biological markers appears to contribute towards improved outcomes and reduced deaths with centhaquine. 

Lyfaquin^® is a frontline therapy used in conjunction with the standard of care and is well-positioned to address critical unmet needs in hypovolemic shock. Lyfaquin^® is well tolerated, with no serious adverse events attributed to Lyfaquin^®.

About Pharmazz, Inc. 
Pharmazz, Inc. is a privately held company engaged in developing novel products in critical care medicine. Additional information may be found on the Company's website, www.pharmazz.com.  

Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are only predictions based on current information and expectations. They involve many risks and uncertainties, including the risk that Pharmazz, Inc. cannot execute its business plan for lack of capital or other resources, distribution, partnering, or licensing/acquisition opportunities. Actual events or results may differ materially from those projected in such statements due to various factors. Any of these risks could cause Pharmazz, Inc. or its industry's actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements in this presentation. Pharmazz, Inc. does not intend to update any forward-looking statements to conform these statements to actual results except as required by applicable law.

SOURCE Pharmazz, Inc.